Global Compact International Yearbook 2014

SanOFI
3. Evaluating and mitigating risks
linked to human rights
Sanofi adopts a proactive strategy to manage
risks related to our business. To implement
this strategy and to address all risks
that we may be exposed to in connection
with our activities, we rely on a dedicated
risk-management organization, including
a Risk Committee, which is chaired by
the Senior Vice-President of CSR; a Risk
Coordination Direction, which is part of
the CSR Direction; and Risk Coordinators,
who are responsible for risk assessments
within their areas of responsibility.
In 2013, under the coordination of the
Group Risk Management Direction, a
working group was established in order
to provide a risk profile on Social and Human
Rights within Sanofi and at the level
of its suppliers; to propose actions plans
when relevant; and to monitor critical
risks. The recommendations made by the
working group will be evaluated in 2014
by the Group Risk Committee for further
implementation of relevant actions.
4. Performing due diligence
assessments of operations and
evaluations of suppliers
As a supplement to the work done in line
with the guide “Human Rights in Our
Activities,” we encourage and enable the
Group’s different functions to evaluate
the impact of their own activities, with
a particular focus on identifying any
potential human rights concerns.
Self-assessment at the Group level: Evaluation
of Sanofi’s practices at the corporate
level is based on the Business and
Human Rights Matrix of the Business
Leaders Initiative for Human Rights,
which allows the Group to establish an
inventory of practices and identify any
areas for improvement.
Local self-assessment: The CSR Excellence
Direction also performed a self-assessment
of practices in a pilot country, India,
selected on the basis of potential risks
of human rights concerns according to
the Maplecroft methodology. This evaluation
was performed using the Human
Rights Assessment Tool for Pharmaceutical
Companies created by the Danish
Institute for Human Rights. The results
of this assessment were encouraging
and highlighted India as an example
for other countries to follow.
We also designed and deployed a specific
risk-methodology to identify and assess
suppliers that should receive priority attention
in terms of evaluation and monitoring
for CSR risks, and Human Rights
risks in particular. A combination of 34
procurement categories and 36 countries
have been targeted as priorities in our
suppliers’ evaluation campaign: A total
of 335 suppliers have been evaluated
since the start of our campaigns in 2011.
5. Training senior executives and
operational managers
SanOFI PeDIatrIC
HeaLtHCare InItIatIve
Since 2010, a total of 84 managers and
senior executives representing more than
25 functions have received one full day of
training about human rights in business.
In-house human rights training sessions
are organized with the support of outside
experts. These experts help prepare the
training program, which includes “case
study” workshops relating to the human
rights issues that Sanofi addresses. The
training sessions also provide an opportunity
to regularly discuss and share best
practices. The human rights program is
part of the training catalog available on
the dedicated training platform accessible
to all Sanofi employees in France.
6. Our focus on children’s rights
Our commitment to respect children’s
rights and to integrate this dimension
into our operations is part of our human
rights approach and complies with the
Children’s Rights and Business Principles
developed by UNICEF in March 2012
alongside the UN Global Compact and
Save the Children project. It represents
the first time comprehensive guidance
has been offered to companies on how
to integrate children’s rights into their
policies and business processes.
As a healthcare company, we have a
particular duty to both ensure that our
products and services are safe for children
and to support children’s rights
through them. Today, Sanofi is the only
pharmaceutical company to offer a vast
portfolio of pediatric products that covers
41 percent of the molecules and vaccines
on the World Health Organization’s Essential
Medicines List for Children.
In Africa, since the launch of the pediatric
initiative, we have made 36 pediatric
products available on the market that
A Sanofi pediatric healthcare initiative has been created to acknowledge our
company-wide commitment to children’s health and to unify our pediatric resources
across all division and brands to better answer children’s health needs.
This initiative, called “Healthy Children, Happy Children,” focuses on pediatric
care in emerging markets (e.g., Africa, Latin America). We are already the
leading pharmaceutical company in these markets, the one with the longest,
most dependable presence in providing medications and services as well as in
developing productive relationships. Our goal, now more than ever, is to provide
every child the opportunity to lead a healthier and happier life.
86 Global Compact International Yearbook 2014